Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(02): 137-141
DOI: 10.1055/s-0042-1750335
Original Article

The Relationship between Pathological Features and 18F-FDG PET/CT that Changed the Surgeon's Decision as Neoadjuvant Therapy in Breast Cancer

Akay Edizsoy 
1   Clinic of Surgical Oncology, Isparta City Hospital, Isparta, Turkey
,
Ahmet Dağ 
2   Clinic of General Surgery, Mersin University, Faculty of Medicine, Mersin, Turkey
,
Pınar Pelin Özcan 
3   Clinic of Nuclear Medicine, Mersin University, Faculty of Medicine, Mersin, Turkey
,
Zehra Pınar Koç 
3   Clinic of Nuclear Medicine, Mersin University, Faculty of Medicine, Mersin, Turkey
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective Patients diagnosed with breast cancer and decided to undergo surgical treatment can undergo neoadjuvant therapy following their 2-deoxy-2-[fluorine-18]fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) findings. The present study aims to determine the statistical significance of these patients whose treatment plan was changed and the reasons for the change in the plan.

Materials and Methods The demographic features and treatment plans of 151 cases who were diagnosed with any stage of breast cancer were evaluated. These patients consist of those who admitted to Mersin University Hospital Breast Outpatient Clinic between January 2016 and December 2019. All of these patients aged between 41 and 85 years were examined with 18F-FDG PET/CT after the decision for surgical treatment is made. The analysis included tumor pathology, side, type, subtype, size, and centricity in this study.

Results About 18.5% (n = 28) of patients' treatment plan was changed after 18F-FDG PET/CT. They received neoadjuvant therapy. About 81.5% (n = 123) of patients did not receive neoadjuvant therapy. Significant differences were observed between patients changed treatment plan and not changed concerning age, lymph node involvement, tumor size, centricity, and subtypes parameters.

Conclusion Conventional imaging examinations are used in patients with breast cancer. These examinations may not be sufficient to determine advanced disease requiring neoadjuvant treatment. With 18F-FDG PET/CT examination, these advanced stage patients are not overlooked. In our study, approximately one in five patients, treatment plan changed after 18F-FDG PET/CT examination.

Keywords

breast cancer - PET - subtype - neoadjuvant


Publication History

Article published online:
28 June 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ulaner GA. PET/CT for patients with breast cancer: where is the clinical impact?. AJR Am J Roentgenol 2019; 213 (02) 254-265
    CrossrefPubMedSearch in Google Scholar
  • 2 Hillner BE, Siegel BA, Liu D. et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008; 26 (13) 2155-2161
    CrossrefPubMedSearch in Google Scholar
  • 3 Krammer J, Schnitzer A, Kaiser CG. et al. (18) F-FDG PET/CT for initial staging in breast cancer patients - is there a relevant impact on treatment planning compared to conventional staging modalities?. Eur Radiol 2015; 25 (08) 2460-2469
    CrossrefPubMedSearch in Google Scholar
  • 4 Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools. Oncologist 2020; 25 (02) e231-e242
    Search in Google Scholar
  • 5 Ueda S, Tsuda H, Asakawa H. et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008; 8: 165
    CrossrefPubMedSearch in Google Scholar
  • 6 Cardoso F, Kyriakides S, Ohno S. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30 (08) 1194-1220
    CrossrefPubMedSearch in Google Scholar
  • 7 Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 2006; 93 (02) 109-119
    CrossrefPubMedSearch in Google Scholar
  • 8 Yararbas U, Avci NC, Yeniay L, Argon AM. The value of 18F-FDG PET/CT imaging in breast cancer staging. Bosn J Basic Med Sci 2018; 18 (01) 72-79
    PubMedSearch in Google Scholar
  • 9 Yildirim N, Simsek M, Aldemir MN, Bilici M, Tekin SB. Relationship between 18-FDG-PET/CT and clinicopathological features and pathological responses in patients with locally advanced breast cancers. Eurasian J Med 2019; 51 (02) 154-159
    CrossrefPubMedSearch in Google Scholar
  • 10 Kaufmann M, von Minckwitz G, Mamounas EP. et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012; 19 (05) 1508-1516
    CrossrefPubMedSearch in Google Scholar
  • 11 Bahl S, Alavi A, Basu S, Kumar R, Czerniecki BJ. The role of PET and PET/CT in the surgical management of breast cancer: a review. PET Clin 2009; 4 (03) 277-287
    CrossrefPubMedSearch in Google Scholar
  • 12 Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast 2011; 20 (06) 491-494
    CrossrefPubMedSearch in Google Scholar
  • 13 Bernsdorf M, Berthelsen AK, Wielenga VT. et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol 2012; 23 (09) 2277-2282
    CrossrefPubMedSearch in Google Scholar
  • 14 Guller U, Nitzsche EU, Schirp U. et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!. Breast Cancer Res Treat 2002; 71 (02) 171-173
    CrossrefPubMedSearch in Google Scholar
  • 15 Senkus E, Kyriakides S, Ohno S. et al; ESMO Guidelines Committee. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v8-v30
    CrossrefPubMedSearch in Google Scholar
  • 16 Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol 2015; 25 (04) 1172-1181
    CrossrefPubMedSearch in Google Scholar
  • 17 Kajáry K, Lengyel Z, Tőkés AM, Kulka J, Dank M, Tőkés T. Dynamic FDG-PET/CT in the initial staging of primary breast cancer: clinicopathological correlations. Pathol Oncol Res 2020; 26 (02) 997-1006
    CrossrefPubMedSearch in Google Scholar
  • 18 Li Y, Dai Y, Guo Y, Wang J, Duan X. Correlation analysis of 18F-FDG PET/CT for the staging and treatment effect assessment of breast cancer. J XRay Sci Technol 2019; 27 (06) 1131-1144
    PubMedSearch in Google Scholar